Lopinavir/Ritonavir (Kaletra) is a combination of the antivirals Lopinavir and Ritonavir, that were originally designed to inhibit HIV from replicating by binding to the protease. Similarly, it has been postulated that the drug could also bind to the protease of SARS-CoV-2. The drug is currently being tested for the treatment of COVID-19.
Tags: ABCB1, ACE2, ADIPONECTIN, ALANINE TRANSAMINASE, ARTIFICIAL, ASPARTATE AMINOTRANSFERASE, AST, CD4, COVID-19, HETEROLOGOUS, IL1B, IL6, IMMUNITY, INSEMINATION, INTERFERON, LACTATE DEHYDROGENASE, LDH, LOPINAVIR; RITONAVIR, LYMPHOCYTE COUNT, MYALGIA, OXIDATIVE STRESS, RESPIRATION, S PROTEIN, SARS-COV-2, SEROCONVERSION, TMPRSS2, TNF